Stock Track | Madrigal Pharmaceuticals Plummets 8.75% in Pre-Market on Wider-Than-Expected Q4 Net Loss

Stock Track02-19 22:46

Madrigal Pharmaceuticals' stock experienced a sharp decline in pre-market trading, plummeting 8.75% following the release of its fourth-quarter financial results.

The biopharmaceutical company reported a quarterly net loss of $2.57 per share, significantly missing analyst estimates which ranged from a loss of $0.40 to $0.90 per share. This wider-than-expected loss occurred despite the company's revenue of $321.1 million beating consensus estimates of $312.5 million, driven by strong sales of its Rezdiffra treatment for metabolic dysfunction-associated steatohepatitis (MASH).

The substantial earnings miss prompted a negative reaction from investors, overshadowing the positive revenue performance and leading to the significant pre-market sell-off in Madrigal's shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129606368?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129606368","market":"nz","top_or_hot":-1,"title":"Stock Track | Madrigal Pharmaceuticals Plummets 8.75% in Pre-Market on Wider-Than-Expected Q4 Net Loss","media":"Stock Track","content":"<p>Madrigal Pharmaceuticals' stock experienced a sharp decline in pre-market trading, plummeting 8.75% following the release of its fourth-quarter financial results.</p><p>The biopharmaceutical company reported a quarterly net loss of $2.57 per share, significantly missing analyst estimates which ranged from a loss of $0.40 to $0.90 per share. This wider-than-expected loss occurred despite the company's revenue of $321.1 million beating consensus estimates of $312.5 million, driven by strong sales of its Rezdiffra treatment for metabolic dysfunction-associated steatohepatitis (MASH).</p><p>The substantial earnings miss prompted a negative reaction from investors, overshadowing the positive revenue performance and leading to the significant pre-market sell-off in Madrigal's shares.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Madrigal Pharmaceuticals Plummets 8.75% in Pre-Market on Wider-Than-Expected Q4 Net Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Madrigal Pharmaceuticals Plummets 8.75% in Pre-Market on Wider-Than-Expected Q4 Net Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-19 22:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Madrigal Pharmaceuticals' stock experienced a sharp decline in pre-market trading, plummeting 8.75% following the release of its fourth-quarter financial results.</p><p>The biopharmaceutical company reported a quarterly net loss of $2.57 per share, significantly missing analyst estimates which ranged from a loss of $0.40 to $0.90 per share. This wider-than-expected loss occurred despite the company's revenue of $321.1 million beating consensus estimates of $312.5 million, driven by strong sales of its Rezdiffra treatment for metabolic dysfunction-associated steatohepatitis (MASH).</p><p>The substantial earnings miss prompted a negative reaction from investors, overshadowing the positive revenue performance and leading to the significant pre-market sell-off in Madrigal's shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1129606368","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129606368","pubTimestamp":1771512378,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Madrigal Pharmaceuticals' stock experienced a sharp decline in pre-market trading, plummeting 8.75% following the release of its fourth-quarter financial results.The biopharmaceutical company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc."},"translate_title":"个股追踪|马德里加尔制药盘前暴跌8.75%Q4净亏损超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1},"content_text":"Madrigal Pharmaceuticals' stock experienced a sharp decline in pre-market trading, plummeting 8.75% following the release of its fourth-quarter financial results.The biopharmaceutical company reported a quarterly net loss of $2.57 per share, significantly missing analyst estimates which ranged from a loss of $0.40 to $0.90 per share. This wider-than-expected loss occurred despite the company's revenue of $321.1 million beating consensus estimates of $312.5 million, driven by strong sales of its Rezdiffra treatment for metabolic dysfunction-associated steatohepatitis (MASH).The substantial earnings miss prompted a negative reaction from investors, overshadowing the positive revenue performance and leading to the significant pre-market sell-off in Madrigal's shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129606368","isCrawlerRequest":true}